Browsing by Author "Anand, Inder"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
    (2020) Teerlink, John R.; Diaz, Rafael; Felker, G. Michael; McMurray, John J. V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sorensen, Tor; Bohm, Michael; Bonderman, Diana; Cleland, John G. F.; Corbalan, Ramon; Crespo-Leiro, Maria G.; Dahlstrom, Ulf; Echeverria Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Candida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin-ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J. A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E.
    Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.